JP2007099665A - Lipid accumulation inhibitor in liver - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new lipid accumulation inhibitor in the liver by discovering a new function of Ganoderma amboinense and for enlarging the application of the Ganoderma amboinense. <P>SOLUTION: The lipid accumulation inhibitor in the liver contains a treated product of the Ganoderma amboinense as an active ingredient. The food contains the lipid accumulation inhibitor in the liver. The lipid accumulation inhibitor in the liver or the food can be used for prevention or amelioration of fatty liver because of having excellent activities for inhibiting the accumulation of neutral fat in the liver. The inhibitor or the food can also be used for prevention of not only the fatty liver but also a symptom of cirrhosis, diabetes, hyperlipemia, hypertension, arteriosclerosis or the like of which the risk heightened by the fatty liver is pointed out. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a hepatic lipid accumulation inhibitor comprising as an active ingredient a processed product of Kazuno Ganoderma.

Kazuno Ganoderma is a type of ganoderma that is a mushroom of the Sarnosidaceae family, and its body is branched like a deer antler. Ganoderma extract is used as a bittering agent and, like other mushrooms, is known to be rich in β-glucan, a polysaccharide, and has an immunostimulatory effect such as an antitumor effect. (Patent Documents 1 and 2).
JP 2005-35898 A JP 2002-53481 A

  However, although Kazuno Ganoderma is in a state where it is becoming clear that it has an action different from that of a ganoderma having an umbrella with spore formation for which the above action has been clarified, There was a problem of being narrow.

  In recent years, due to dietary changes, fat (sugar, sugar, alcohol, especially neutral fat) is accumulated in the liver due to excessive intake of fat, sugar and alcohol. There is an increase in fatty liver. Furthermore, it has been pointed out that fatty liver increases the risk of cirrhosis, diabetes, hyperlipidemia, hypertension and arteriosclerosis.

  This invention is made | formed in view of the said problem, Comprising: The objective is to provide the lipid improving agent in a liver (henceforth liver).

  The present inventor has intensively studied the functionality of Kakuno Ganoderma and found that the Kakuno Ganoderma treated product has an excellent liver lipid improving effect and has completed the present invention.

  That is, this invention relates to the lipid accumulation inhibitor in a liver which uses the Kakuno Reishi processed material as an active ingredient.

  The present invention also relates to a food composition or a pharmaceutical composition containing the liver lipid accumulation inhibitor.

  The hepatic lipid accumulation inhibitor comprising the processed deer anteater of the present invention as an active ingredient has an excellent liver lipid improving effect.

  Therefore, the new function of Kakukaku Reishi in improving liver lipids can expand the uses of Kakukaku Reishi and provide an excellent hepatic lipid accumulation inhibitor.

  Hereinafter, embodiments of the present invention will be described. The present invention relates to a hepatic lipid accumulation inhibitor (hereinafter, sometimes referred to as a hepatic lipid accumulation inhibitor of the present invention), which comprises a koji ganshi treated product as an active ingredient. The present invention also relates to a food (hereinafter sometimes referred to as the food of the present invention) containing a liver lipid accumulation inhibitor. In addition, this invention is not restrict | limited by the following embodiment. That is, the present invention can be modified within the scope of the contents described in the claims.

(Liver lipid accumulation inhibitor of the present invention)
The hepatic lipid accumulation inhibitor of the present invention uses Kakuno Reishi treated product. Hereinafter, the Kakuno Ganoderma processed product will be described.

(Kazuno Ganoderma processed product)
In the present invention, the kakukaku reishi treated product refers to a kakukaku reishi which has been subjected to some treatment, such as a dried powder of kakukaku reishi, an extract of kakukaku reishi and its dried powder.

  As a raw material of the processed deer antler reed of the present invention, among the reindeer, a fruit body whose shape is branched like a deer antler is present, and there is an umbrella with some sporulation at the end of the branch. May be.

  The dried kakukaku reishi is obtained, for example, by drying kakaku reishi by sun drying or hot air drying. Drying is preferably performed until the water content becomes 10% by mass or less. In addition, if necessary, the dried deer antaceae may be further pulverized to form a powder.

  In the case of obtaining dried kakukakureishi powder, the powdering method may be, for example, a method commonly used by those skilled in the art, such as ball mill, hammer mill, roller mill, etc. The method of doing is mentioned. Of course, a method may be used in which the deer antler turf before drying is pulverized in advance with a mass collider, a slicer or a comitoroll, and the pulverized product is dried.

  A kakukaku reishi extract can be obtained by adding a solvent to kakukaku reishi and heating as necessary. Of course, the extract may be obtained by collecting the extract by centrifugation or filtration. In addition, although the kakukaku reishi used before obtaining an extract may be a kakukaku reishi before drying, it is preferable that it is a kakukaku reishi after drying (for example, kakukaku reishi dry powder).

  Examples of the solvent that can be used in the case of obtaining the kakukaku reishi extract include water, organic solvents, water-containing organic solvents, and the like. Moreover, as an organic solvent here, methanol, ethanol, n-propanol, n-butanol, acetone, hexane, cyclohexane, propylene glycol, ethyl methyl ketone, glycerin, methyl acetate, ethyl acetate, diethyl ether, dichloromethane, edible fats and oils 1,1,1,2-tetrafluoroethane, 1,1,2-trichloroethene and the like. Among them, preferred organic solvents in the case of obtaining an extract of Kazuno Ganoderma are water, polar organic solvents and hydrous polar organic solvents, more preferably water, ethanol, n-butanol, methanol, acetone, propylene glycol, ethyl acetate. These hydrated substances are most preferably water, ethanol and hydrated ethanol.

  In the case of extracting by heating, examples of the method include a heating extraction method such as heating and reflux, a supercritical extraction method, and the like. When heating, it is necessary to prevent volatilization of the solvent added to Kakuno Reishi, but the lower limit of the temperature during the heating is 50 ° C. or higher, preferably 70 ° C. or higher. Is set to 130 ° C. or lower, preferably 100 ° C. or lower.

  The time required for the extraction may be a time for sufficiently extracting the soluble component from Kazuno Ganoderma, and is preferably 30 minutes to 48 hours. In addition, when heating is not performed, that is, when extraction is performed at less than 50 ° C., it is preferable to immerse for 6 to 48 hours, and when heating is performed at 50 ° C. or more, heating may be performed for 30 minutes to 24 hours. .

  Further, for example, the obtained extract (extract) may be concentrated or dried by vacuum concentration, lyophilization, or the like as necessary, for example, by removing an organic solvent. Of course, such a concentrated extract or a dried extract may be used as the kakukaku reishi treated product of the present invention.

(Liver lipid accumulation inhibitor of the present invention)
The hepatic lipid accumulation inhibitor of the present invention contains a processed product of Kazuno Ganoderma. By containing these components, an excellent inhibitory effect on lipid accumulation in the liver can be obtained. Furthermore, if a lipid absorption inhibiting component or a lipid metabolism promoting component described later is added, a synergistic effect with that component can be expected. In other words, a combination of a kakukaku reishi component and a lipid absorption inhibiting component or a lipid metabolism promoting component can be expected to have an excellent effect, rather than simply a combination of a sugar or lipid absorption inhibiting component or a metabolism promoting component.

  There is no restriction | limiting in particular in the compounding quantity of these each component. However, the blended amount of dried kakukakushika is preferably blended so that the lower limit of the intake of dried kakukakushika per adult day is 0.1 g or more. Moreover, it is good to mix | blend so that the upper limit of the intake amount of the kakukaku reishi thing per day for an adult may be 50 g or less, Preferably it is 30 g or less.

(Food of the present invention)
The food of the present invention contains a liver lipid accumulation inhibitor. In other words, it contains the Kazuno Ganoderma processed product.

  Since the blending amount of the kakukaku reishi treated product or the like varies depending on the form and dosage form, it may be appropriately adjusted. For example, in the case of dried kakukaku reishi, the lower limit of dried kakushi reishi is 0.001% by mass or more, preferably 0.01% by mass or more. The upper limit of the product is 80% by mass or less, preferably 50% by mass or less.

  In addition, excipients, extenders, binders, thickeners, emulsifiers, colorants, fragrances, other food ingredients, seasonings, pharmaceutical ingredients, etc. may be added to the food of the present invention as necessary. Also good. Furthermore, the food containing the hepatic lipid accumulation inhibitor of the present invention may be formed into a form such as a granule or a tablet depending on the application. As for the dosage form of the food to which the ingredients of the present invention are added, capsules such as hard capsules and soft capsules, tablets or pills as necessary, or powder, granules, tea, tea bags, Or it can shape | mold into forms, such as a bowl shape, or can be used as it is as a drink. Depending on their shape or preference, they may be eaten as they are, or they may be dissolved in water, hot water, milk or the like. In the case of powdered tea bags, etc., the ingredients may be leached before drinking.

  Examples of food materials that can be added to the food of the present invention include royal jelly, propolis, vitamins (A, C, D, E, K, folic acid, pantothenic acid, biotin, derivatives thereof, etc.), minerals (iron, magnesium) , Calcium, zinc, etc.), selenium, α-lipoic acid, lecithin, polyphenols (flavonoids, derivatives thereof, etc.), carotenoids (lycopene, astaxanthin, zeaxanthin, lutein, etc.), xanthine derivatives (eg caffeine), fatty acids, proteins (Collagen, elastin, etc.), mucopolysaccharide (hyaluronic acid, etc.), amino sugar (glucosamine, acetylglucosamine, galactosamine, acetylgalactosamine, neuraminic acid, acetylneuraminic acid, hexosamine, salts thereof), oligosaccharide (isomaltoo Sugar sugars, cyclic oligosaccharides, etc.), sphingolipids and phospholipids and their derivatives (phosphatidylcholine, sphingomyelin, ceramide, etc.), sulfur-containing compounds (eg, alliin, sepaene, taurine, glutathione, methylsulfonylmethane), sugar alcohols Lignans (such as sesamin), plant and animal extracts containing these, root vegetables (turmeric, ginger, etc.), green leaves of gramineous plants such as wheat powder and green leaves of cruciferous plants such as kale.

  In particular, in the present invention, if not only the above-described Kazuno Ganoderma treated product but also at least one of a lipid absorption inhibiting component and a lipid metabolism promoting component is added, a synergistic lipid accumulation inhibiting or body fat reducing effect is obtained. be able to. As a result, for example, an antidiabetic effect and a preventive effect for various symptoms caused by obesity can be expected.

  Examples of the lipid absorption-suppressing component herein include components having an action to excrete bile acids such as chitosan and its derivatives, psyllium and proanthocyanidins, and components having a lipase inhibitory action such as gallotannins and loquat leaves and extracts thereof. Is mentioned. In addition, for example, a plant extract containing a large amount of proanthocyanidins such as a pine bark extract can be used as the proanthocyanidins.

  Lipid metabolism promoting components include riboflavins, tea catechins, isomerized linoleic acid, caffeine, capsaicin, carnitine, coenzyme Q10, soy peptide, branched amino acid, phosphatidylcholine, allyl sulfide compound, forskolin, bergenin, quercetin , Astilbine, hydroxycitric acid, and salts thereof. Of course, plant extracts containing these lipid metabolism promoting components, for example, extracts of tea, coleus foli, red pepper, yellow potato, soybean, chili, buckwheat, garlic, onion, coffee, etc. are used as lipid metabolism promoting components. It is also possible.

  The lipid absorption suppressing component and the lipid metabolism promoting component are appropriately blended depending on the purpose. For example, only one of the lipid absorption suppressing component and the lipid metabolism promoting component may be added, or both the lipid absorption suppressing component and the lipid metabolism promoting component may be added. Of course, two or more lipid absorption inhibiting components may be added, or two or more lipid metabolism promoting components may be added.

  In particular, Kakukaku Reishi is a so-called “green juice” that is eaten as a drink by powdering green leaves such as barley young leaves (eg, barley young leaves), kale, tomorrow leaves, and mulberry leaves that have been eaten for health in recent years. By using a processed product, it can be made into a green juice that has better palatability than other green juices due to a synergistic effect with water, and by combining with other green juice ingredients that are difficult to ingest, It is also possible to make it easier to take green juice ingredients. Furthermore, it can be used for beverages containing the above-mentioned food materials, for example, plant fermented juice, vegetable juice (for example, carrot juice), plant extract, fruit juice, etc. Not only can it be better, it can also be a functional or nutritious beverage.

  Of course, in a food containing the hepatic lipid accumulation inhibitor of the present invention, a sugar solution, sugar alcohol, seasoning or the like can be added to enhance the sweetness.

  The dosage form of the food containing the hepatic lipid accumulation inhibitor of the present invention may be a capsule such as a hard capsule or a soft capsule, a tablet or a pill as necessary, or a powder, granule or tea. It can be formed into a tea bag shape or a bowl shape or used as a beverage as it is. Depending on their shape or preference, they may be eaten as they are, or they may be dissolved in water, hot water, milk or the like. In the case of powdered tea bags, etc., the ingredients may be leached before drinking.

  Hereinafter, the present invention will be described based on examples. Note that the present invention should not be construed as being limited by the description of the embodiments, and various modifications can be made within the scope of the claims.

(Example 1: Preparation of Kazuno Reishi dry powder)
100 g of fruit body of Kazuno Reishi was warm-air dried (primary drying) at 70 ° C. for 2 hours in a dryer until the water content was about 15% by mass. Next, hot air drying (secondary drying) was performed at 80 ° C. for 4 hours so that the final moisture content was 10% by mass. Next, steam sterilization was performed using a saturated water pressure of 150 ° C. for 3 seconds. At this time, after the water contained in the sweet potato leaves was dried, it was finely pulverized using a hammer mill so that 90% by mass passed through the 200 mesh section to obtain a dried powder (80 g) of deer antler.

(Example 2: Cultivation of sample for evaluation of liver lipid improving action)
A sample for evaluation of an action for improving lipid in liver was cultured by the following method using the dried powder of deer antrum prepared in Example 1.

  HepG2 cells (human liver tumor cells; RIKEN) are seeded at 2 × 10 4 cells / well in a 96-well plate, and 0.1 mL of standard medium (DMEM medium containing 1.5% by volume bovine serum albumin; (Manufactured by Sigma-Aldrich) for 24 hours at 37 ° C. in a 5% CO 2 atmosphere. Thereafter, the medium was replaced with a standard medium containing 1.5 mM oleic acid (manufactured by Sigma-Aldrich) and 3 μg / mL deer horned turf dry powder, and cultured at 37 ° C. for 24 hours in a 5% CO 2 atmosphere. The cultured medium was washed three times with PBS, and then the HepG2 cells were disrupted by freezing and thawing the entire medium in PBS to obtain a cell disruption solution.

  Test group 2 was a cell lysate obtained by culturing in the same manner as in test group 1 except that the kakushigaku reishi dried powder was changed to 10 μg / mL.

  The comparative group was a cell lysate obtained by culturing in the same manner as in test group 1 except that the replaced medium was a standard medium containing only 1.5 mM oleic acid.

  Control group 1 was a cell disruption solution obtained by culturing in the same manner as in test group 1 except that the replaced medium was used as the standard medium.

(Example 3: Evaluation 1 of liver lipid improving action)
About each cell crushing liquid obtained in Example 2, the amount of neutral fat was measured with the measurement kit (Triglyceride G-Test Wako; Wako Pure Chemical Industries, Ltd.). At that time, the ratio (%) when the average value of the amount of neutral fat in the control group 1 was taken as 100% was calculated. The results are shown in Table 1.

(Example 4: Evaluation 2 of liver lipid improving action)
For each cell disruption solution obtained in Example 2, mitochondrial dehydrogenase (WST-1), which is a marker indicating cell activation, was measured using a measurement kit (Cell Counting Kit; Dojin Chemical Co., Ltd.). In that case, the ratio (%) when the average value of the WST-1 value of the control group 1 was set to 100% was calculated. The results are shown in Table 1. In addition, it shows that the activation of a cell is improving, so that WST-1 value is high.

  As a result of Table 1, test group 1 and test group 2 using a medium containing dried kakukaku reishi powder and oleic acid have a lower amount of neutral fat than the comparative group using a medium containing only oleic acid. You can see that Furthermore, about WST-1 which is a marker which shows activation of a cell, it turns out that hepatocytes can be activated from the test group 1 and the test group 2 being increased compared with a comparison group.

  Therefore, it can be seen that the liver lipid accumulation inhibitor of the present invention has an excellent inhibitory effect on lipid accumulation in the liver and can be used as an agent for improving liver function by activating cells. Furthermore, the liver lipid accumulation inhibitor of the present invention has an excellent liver neutral fat accumulation inhibitory action, and it has been pointed out that the risk increases due to fatty liver, diabetes, hyperlipidemia, hypertension, It can also be expected to prevent symptoms such as arteriosclerosis.

The hepatic lipid accumulation inhibitor comprising the processed deer anteater of the present invention as an active ingredient is useful because it has an excellent inhibitory effect on hepatic lipid accumulation.

Claims (2)

  Inhibitor of hepatic lipid accumulation containing Kakuno Ganoderma treated product as an active ingredient. A food composition or a pharmaceutical composition comprising the hepatic lipid accumulation inhibitor according to claim 1.